1Yutaka OKI. Medical Management of Functioning Pituitary Ad- enoma : An Update. Neurol Med Chir, 2014,54 ( 12 ) : 958 - 965.
2Wong A J, Eloy JA, Couldwell WT, et al. Update on prolacti- nomas. Part 2: Treatment and management strategies. Clin Neurosci. 2015,22(10) :1568-1574.
3Yang MS, Hong JW, Lee SK, et al. Clinical management and outcome of 36 invasive prolactinomas treated with dopa- mine agonist. J Neurooneo1,2011 , 104 ( 1 ) : 195-204.
4Anagnostis P, Amidou F, Stergios A. et al. Long term fol- low-up of patients with prolactinomas and outcome of dopa- mine agonist withdrawal:a single center experience. Pituitary, 2012,15(1) :25-29.
5Cho KR, Jo KI, Shin HJ. Bromocriptine Therapy for the Treat- ment of Invasive Prolactinoma: The Single Institute Experi- ence. Brain Tumor Res Treat, 2013,1 (2) :71-77.
6Almalki M, Buhary B, Alzahrani S et al. Giant prolaetinomas : clinical manifestations and outcomes of 16 Arab cases. Pituita- ry,2015, (18) :405-409.
7Rastogi A, Bhansali A, Dutta P, et al. A comparison between intensive and conventional cabergoline treatment of newly diag- nosed patients with macroprolactinoma. Clinical Endocrinology, 2013,79 (3) :409-415.
8Espinosa E, Sosa E, Mendoza V, et al. Giant prolactinomas : are they really different from ordinary macroprolactinomas ? En- docrine, 2016,52(3 ) :652-659.
9Arduc A, Gokay F, Isik S, et al. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience. J Endocrinol Invest, 2015, 38 (4) :447-453.
10Kurosaki M, Kambe A, Watanabe T, et al. Serial 3 T magnetic resonance imaging during cabergoline treatment of macroprolacti- nomas. Neurological Research, 2015 , 37 ( 4 ) : 341 - 346.
